Can we ignore minimal hepatic encephalopathy any longer?
Qadri
Asif M
AM
Ogunwale
Ben O
BO
Mullen
Kevin D
KD
D004187:Disaccharides / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006501:Hepatic Encephalopathy / Q000188:drug therapy / Q000453:epidemiology* / Q000523:psychology*; D006801:Humans; D015994:Incidence; D007792:Lactulose / Q000009:adverse effects / Q000627:therapeutic use; D011594:Psychometrics; D011788:Quality of Life / Q000523:psychology*; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin
D004187:Disaccharides; D005765:Gastrointestinal Agents; D012294:Rifamycins; D007792:Lactulose; D000078262:Rifaximin